141 related articles for article (PubMed ID: 34342490)
1. Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study.
Abdel-Rahman O; Wu C; Easaw J
Future Oncol; 2021 Oct; 17(30):3977-3986. PubMed ID: 34342490
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study.
Lee I; Adimadhyam S; Nutescu EA; Zhou J; Asfaw AA; Sweiss KI; Patel PR; Calip GS
Pharmacotherapy; 2019 Sep; 39(9):921-928. PubMed ID: 31332810
[TBL] [Abstract][Full Text] [Related]
3. Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer.
Abdel-Rahman O; Koski S; Mulder K
Int J Colorectal Dis; 2021 Mar; 36(3):493-499. PubMed ID: 33068162
[TBL] [Abstract][Full Text] [Related]
4. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database.
Matsumura C; Chisaki Y; Sakimoto S; Sakae H; Yano Y
J Oncol Pharm Pract; 2018 Jan; 24(1):22-27. PubMed ID: 27856923
[TBL] [Abstract][Full Text] [Related]
6. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Suenaga M; Mizunuma N; Kobayashi K; Shinozaki E; Matsusaka S; Chin K; Kuboki Y; Ichimura T; Ozaka M; Ogura M; Fujiwara Y; Matsueda K; Konishi F; Hatake K
Med Oncol; 2010 Sep; 27(3):807-14. PubMed ID: 19697164
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site.
Mahé I; Chidiac J; Bertoletti L; Font C; Trujillo-Santos J; Peris M; Pérez Ductor C; Nieto S; Grandone E; Monreal M;
Am J Med; 2017 Mar; 130(3):337-347. PubMed ID: 27884650
[TBL] [Abstract][Full Text] [Related]
9. Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer.
Gouverneur A; Favary C; Jové J; Rouyer M; Bignon E; Salvo F; Tchalla A; Paillaud E; Aparicio T; Noize P
Target Oncol; 2023 Sep; 18(5):717-726. PubMed ID: 37682504
[TBL] [Abstract][Full Text] [Related]
10. Patterns of colorectal cancer diagnosis among younger adults in a real-world, population-based cohort.
Abdel-Rahman O; Karachiwala H; Koski S
Future Oncol; 2022 Jan; 18(1):47-54. PubMed ID: 34763528
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents.
Roddy JV; Partridge SM; Rockey ML; Pruemer JM; Guo JJ; Desai SJ; Safa MM
Am J Clin Oncol; 2010 Feb; 33(1):36-42. PubMed ID: 19652579
[TBL] [Abstract][Full Text] [Related]
12. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
Tebbutt NC; Murphy F; Zannino D; Wilson K; Cummins MM; Abdi E; Strickland AH; Lowenthal RM; Marx G; Karapetis C; Shannon J; Goldstein D; Nayagam SS; Blum R; Chantrill L; Simes RJ; Price TJ;
Ann Oncol; 2011 Aug; 22(8):1834-8. PubMed ID: 21273347
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.
Alcalay A; Wun T; Khatri V; Chew HK; Harvey D; Zhou H; White RH
J Clin Oncol; 2006 Mar; 24(7):1112-8. PubMed ID: 16505431
[TBL] [Abstract][Full Text] [Related]
15. Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data.
Connelly-Frost A; Shantakumar S; Kobayashi MG; Li H; Li L
BMC Cancer; 2013 Apr; 13():209. PubMed ID: 23621951
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer.
Kapelakis I; Toutouzas K; Drakopoulou M; Michelongona A; Zagouri F; Mpamias A; Pliatsika P; Dimopoulos MA; Stefanadis C; Tousoulis D
Hellenic J Cardiol; 2017; 58(3):215-219. PubMed ID: 28258825
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
Penfound S; Lukey A; Hodgson J; Hopman WM; Hanley GE; Othman M
Gynecol Oncol; 2024 Jun; 185():116-120. PubMed ID: 38382168
[TBL] [Abstract][Full Text] [Related]
18. Risk of postoperative venous thromboembolism after laparoscopic and open colorectal surgery: an additional benefit of the minimally invasive approach?
Shapiro R; Vogel JD; Kiran RP
Dis Colon Rectum; 2011 Dec; 54(12):1496-502. PubMed ID: 22067177
[TBL] [Abstract][Full Text] [Related]
19. Patterns of emergency department visits preceding colorectal cancer diagnosis: a population-based study.
Abdel-Rahman O; Tang PA; Ghosh S; Scarfe A
J Comp Eff Res; 2022 Apr; 11(5):311-318. PubMed ID: 35189709
[No Abstract] [Full Text] [Related]
20. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Cunningham D; Lang I; Marcuello E; Lorusso V; Ocvirk J; Shin DB; Jonker D; Osborne S; Andre N; Waterkamp D; Saunders MP;
Lancet Oncol; 2013 Oct; 14(11):1077-1085. PubMed ID: 24028813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
